{"schema_version":"secwatch.filing_event.v1","accession":"0001711279-24-000055","form_type":"8-K","ticker":"KRYS","cik":"0001711279","company_name":"Krystal Biotech, Inc.","filed_at":"2024-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.308553+00:00","generated_at":"2026-05-30T06:11:19.535323+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Krystal Biotech Q3 net product rev $83.8M; VYJUVEK approvals reach 460; JNDA filed in Japan","bullets":["Net product revenue of $83.8M from VYJUVEK; $250.1M total since Aug 2023 launch.","Net income $27.2M ($0.91 diluted) vs $80.7M ($2.79) in Q3 2023; SG&A rose to $28.7M.","Cash and investments $694.2M; 460+ U.S. reimbursement approvals secured as of October.","JNDA filed for B-VEC in Japan; EMA decision expected before year end; French early access approved.","Guidance: non-GAAP R&D+SG&A $115-125M for FY2024; key pipeline data due by year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001711279-24-000055","json":"https://secwatch.observer/filing/0001711279-24-000055.json","markdown":"https://secwatch.observer/filing/0001711279-24-000055.md","text":"https://secwatch.observer/filing/0001711279-24-000055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711279/000171127924000055/0001711279-24-000055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711279/000171127924000055/krys-20241104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T06:11:19.535323+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}